Post-operative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC)

Timothy J Cooksley, Philip Haji-Michael, Timothy J Cooksley, Philip Haji-Michael

Abstract

Background: Cytoreductive surgery (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC) results in a number of physiological changes with effects on the cardiovascular system, oxygen consumption and coagulation. The Critical Care interventions required by this cohort of patients have not yet been quantified.

Methods: This retrospective audit examines the experience of a Specialist Tertiary Centre in England over an 18 month period (January 2009-June 2010) during which 69 patients underwent CRS and HIPEC. All patients were extubated in the operating theatre and transferred to the Critical Care Unit (CCU) for initial post-operative management.

Results: Patients needed to remain on the CCU for 2.4 days (0.8-7.8). There were no 30 day mortalities. The majority of patients (70.1%) did not require post-operative organ support. 2 patients who developed pneumonia post-operatively required respiratory support. 18 (26.1%) patients required vasopressor support with norepinephrine with a mean duration of 13.94 hours (5-51 hours) and mean dose of 0.04 mcg/kg/min. Post-operative coagulopathy peaked at 24 hours. A significant drop in serum albumin was observed.

Conclusion: The degree of organ support required post-operatively is minimal. Early extubation is efficacious with the aid of epidural analgesia. Critical Care monitoring for 48 hours is desirable in view of the post-operative challenges.

Figures

Figure 1
Figure 1
A checklist for patients undergoing CRS and HIPEC.

References

    1. Smeenk R, Verwaal V, Antonini N, Zoetmulder F. Survival Analysis of Pseudomyoxma Peritonei Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg. 2007;245:104–8. doi: 10.1097/01.sla.0000231705.40081.1a.
    1. Rout S, Renehan A, Parkinson M, Saunders M, Fulford P, Wilson M, O'Dwyer S. Treatments and outcomes of peritoneal surface tumors through a centralized national service (United Kingdom) Dis Colon Rectum. 2009;52:1705–14. doi: 10.1007/DCR.0b013e3181b5504e.
    1. Glockzin G, Schlitt H, Piso P. Peritoneal carcinomatosis: patient selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2009;7:5. doi: 10.1186/1477-7819-7-5.
    1. Jacquet P, Averbach A, Stephens A, Stuart O, Chang D, Sugarbaker P. Heated introperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55:130–8. doi: 10.1159/000011847.
    1. Khatri VP. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer: A Panacea or Just an Obstacle Course for the Patient? J Clin Oncol. 2010;28:5–7. doi: 10.1200/JCO.2009.24.8500.
    1. Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum. 2007;50:37–42. doi: 10.1007/s10350-006-0741-9.
    1. Yan TD, Links M, Xu ZY, Kam P, Glenn D, Morris D. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg. 2006;93:1270–6. doi: 10.1002/bjs.5427.
    1. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and peri-operative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2009;28:63–8.
    1. Kanakoudis F, Petrou A, Michaloudis D, Chortaria G, Konstantinidou A. Anaesthesia for intra-peritoneal perfusion of hyperthermic chemotherapy. Haemodynamic changes, oxygen consumption and delivery. Anaesthesia. 1996;51:1033–6. doi: 10.1111/j.1365-2044.1996.tb14998.x.
    1. Schmidt C, Creutzenberg M, Piso P, Hobbhahn J, Bucher M. Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia. 2008;63:389–95. doi: 10.1111/j.1365-2044.2007.05380.x.
    1. Schmidt C, Moritz S, Rath S, Grossmann E, Wiesenack C, Piso P, Graf B, Bucher M. Perioperative Management of Patients with Cytoreductive Surgery for Peritoneal Carcinomatosis. J Surg Oncol. 2009;100:297–301. doi: 10.1002/jso.21322.
    1. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2:3–10. doi: 10.1186/1477-7800-2-3.
    1. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–31. doi: 10.1007/s10434-999-0727-7.
    1. Ali M, Winter DC, Hanly AM, O'Hagan C, Keaveny J, Broe P. Prospective, randomized, controlled trial of thoracic epidural or patient controlled opiate analgesia on perioperative quality of life. Br J Anaesth. 2010;104:292–7. doi: 10.1093/bja/aeq006.
    1. Behera BK, Puri GD, Ghai B. Patient-controlled epidural analgesia with fentanyl and bupivacaine provides better analgesia than intravenous morphine patient-controlled analgesia for early thoracotomy pain. J Postgrad Med. 2008;54:86–90. doi: 10.4103/0022-3859.40772.
    1. Vorgias G, Iavazzo C, Mavromatis J, Leontara J, Katsoulis M, Kalinoglou N, Akrivos T. Determination of the necessary total protein substitution requirements in patients with advanced stage ovarian cancer and ascites, undergoing debulking surgery. Correlation with plasma proteins. Ann Surg Oncol. 2007;14:1919–23. doi: 10.1245/s10434-007-9404-x.
    1. Schols SE, Lance MD, Feijge MA, Damoiseaux J, Marcus MA, Hamulyák K, Ten Cate H, Heemskerk JW, van Pampus EC. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb Haemost. 2010;103:318–28.
    1. Ahmed S, Oropello JM. Critical care issues in oncological surgery patients. Crit Care Clin. 2010;26:93–106. doi: 10.1016/j.ccc.2009.10.004.
    1. Yan TD, Black D, Savady R, Sugarbaker P. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484–92. doi: 10.1245/s10434-006-9182-x.
    1. Smeenk RM, Verwaal V, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei-a report of 103 procedures. Eur J Surg Oncol. 2006;32:186–90. doi: 10.1016/j.ejso.2005.08.009.
    1. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol. 2007;14:128–33.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren